[Prevalence of anti-HCV in sera of patients with hepatocellular carcinoma].
Antibody to hepatitis C virus (Anti-HCV) was examined in sera of 416 patients with hepatocellular carcinoma (HCC). The prevalence of anti-HCV was 11.1% (46/416), among them, the dual infection rate with HCV and HBV was 5.8% (24/416), in contrast to 2.0% (2/100) in blood donors. Moreover, sera of 38 patients with HCC accompanying with acute hepatitis were tested for anti-HAV, HBsAg and anti-HCV. Their positive rates were: hepatitis A 5.3% (2/38), hepatitis B 76.3% (29/38), hepatitis C 10.5% (4/38), and other hepatitis 7.9% (3/38), respectively. These results indicate that HBV infection seems to be more important than HCV infection in the etiology of HCC in our country. The role of HCV in the development of HCC remains to be further investigated.
Yu
Z Y
ZY
Liver Cancer Institute, Shanghai Medical University.
D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000382:microbiology*; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000097:blood*; D006509:Hepatitis B / Q000276:immunology; D006511:Hepatitis B Antigens / Q000097:blood; D006526:Hepatitis C / Q000276:immunology; D018937:Hepatitis C Antibodies; D006801:Humans; D008113:Liver Neoplasms / Q000276:immunology / Q000382:microbiology*; D015163:Superinfection / Q000276:immunology
D006508:Hepatitis Antibodies; D006511:Hepatitis B Antigens; D018937:Hepatitis C Antibodies